1. Home
  2. ENTX vs VRA Comparison

ENTX vs VRA Comparison

Compare ENTX & VRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

SELL

Current Price

$3.11

Market Cap

147.4M

Sector

Health Care

ML Signal

SELL

Logo Vera Bradley Inc.

VRA

Vera Bradley Inc.

SELL

Current Price

$7.53

Market Cap

156.6M

ML Signal

SELL

Company Overview

Basic Information
Metric
ENTX
VRA
Founded
2010
1982
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Apparel
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
147.4M
156.6M
IPO Year
2015
2010

Fundamental Metrics

Financial Performance
Metric
ENTX
VRA
Price
$3.11
$7.53
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
★ $9.75
N/A
AVG Volume (30 Days)
★ 569.4K
474.4K
Earning Date
11-17-2026
12-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 20.47
EPS
★ 0.22
N/A
Revenue
$42,000.00
★ $416,097,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.56
P/E Ratio
$13.95
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.91
$1.39
52 Week High
$4.20
$7.13

Technical Indicators

Market Signals
Indicator
ENTX
VRA
Relative Strength Index (RSI) 56.02 81.50
Support Level $2.64 $3.05
Resistance Level $3.26 N/A
Average True Range (ATR) 0.24 0.35
MACD 0.03 0.03
Stochastic Oscillator 70.00 90.97

Price Performance

Historical Comparison
ENTX
VRA

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

About VRA Vera Bradley Inc.

Vera Bradley Inc designs women's handbags, luggage, and travel items, fashion and home accessories, and gifts. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct and Vera Bradley Indirect.

Share on Social Networks: